Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Aclaris Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aclaris Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$62.06M. For fiscal 2025 it was -$47.11M. The highest annual figure on record is -$4.92M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$47.11M | – |
| FY2024 | Dec 31, 2024 | -$20.08M | – |
| FY2023 | Dec 31, 2023 | -$78.33M | – |
| FY2022 | Dec 31, 2022 | -$67.57M | – |
| FY2021 | Dec 31, 2021 | -$52.13M | – |
| FY2020 | Dec 31, 2020 | -$38.63M | – |
| FY2019 | Dec 31, 2019 | -$96.45M | – |
| FY2018 | Dec 31, 2018 | -$100.81M | – |
| FY2017 | Dec 31, 2017 | -$54.66M | – |
| FY2016 | Dec 31, 2016 | -$34.60M | – |
| FY2015 | Dec 31, 2015 | -$20.37M | – |
| FY2014 | Dec 31, 2014 | -$7.64M | – |
| FY2013 | Dec 31, 2013 | -$4.92M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.13M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.93M | -149.7% |
| Q2 FY2025 | Jun 30, 2025 | -$9.99M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.94M | – |
| Q3 FY2024 | Sep 30, 2024 | $22.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.97M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.61M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.15M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.39M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.36M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$31.32M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.25M | – |
| Q3 FY2018 | Sep 30, 2018 | -$29.86M | – |
| Q2 FY2018 | Jun 30, 2018 | -$21.83M | – |
| Q1 FY2018 | Mar 31, 2018 | -$21.87M | – |
| Q4 FY2017 | Dec 31, 2017 | -$18.21M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.66M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.07M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.91M | – |
See a number that looks wrong?